Finally, we demonstrate that the synergistic cytotoxicity observed in vitro translates into anti-tumor effects in vivo, supporting the therapeutic potential of targeting CDK7 and BRD4 in combination in NB. The gene discussed is CDK7; the disease is neuroblastoma.